nodes	percent_of_prediction	percent_of_DWPC	metapath
Floxuridine—TYMS—ovarian cancer	0.762	1	CbGaD
Floxuridine—TYMP—myometrium—ovarian cancer	0.00419	0.0886	CbGeAlD
Floxuridine—TYMP—Nucleotide metabolism—NME2—ovarian cancer	0.00381	0.0831	CbGpPWpGaD
Floxuridine—TYMP—uterine cervix—ovarian cancer	0.00326	0.069	CbGeAlD
Floxuridine—TYMP—decidua—ovarian cancer	0.0031	0.0657	CbGeAlD
Floxuridine—TYMP—endometrium—ovarian cancer	0.00295	0.0624	CbGeAlD
Floxuridine—TYMS—uterine cervix—ovarian cancer	0.0028	0.0592	CbGeAlD
Floxuridine—TYMP—uterus—ovarian cancer	0.00272	0.0575	CbGeAlD
Floxuridine—TYMS—endometrium—ovarian cancer	0.00253	0.0535	CbGeAlD
Floxuridine—TYMP—female reproductive system—ovarian cancer	0.00244	0.0517	CbGeAlD
Floxuridine—TYMS—gonad—ovarian cancer	0.00235	0.0496	CbGeAlD
Floxuridine—TYMP—bone marrow—ovarian cancer	0.00231	0.0488	CbGeAlD
Floxuridine—TYMS—Docetaxel—Paclitaxel—ovarian cancer	0.00222	0.472	CbGdCrCtD
Floxuridine—TYMP—Pyrimidine metabolism—TYMS—ovarian cancer	0.00222	0.0484	CbGpPWpGaD
Floxuridine—TYMP—female gonad—ovarian cancer	0.00222	0.047	CbGeAlD
Floxuridine—TYMP—vagina—ovarian cancer	0.00221	0.0467	CbGeAlD
Floxuridine—TYMS—female reproductive system—ovarian cancer	0.00209	0.0443	CbGeAlD
Floxuridine—TYMS—bone marrow—ovarian cancer	0.00198	0.0419	CbGeAlD
Floxuridine—TYMP—testis—ovarian cancer	0.00197	0.0417	CbGeAlD
Floxuridine—Cladribine—NR5A1—ovarian cancer	0.00196	0.369	CrCbGaD
Floxuridine—TYMS—Nucleotide metabolism—NME2—ovarian cancer	0.00195	0.0425	CbGpPWpGaD
Floxuridine—TYMS—female gonad—ovarian cancer	0.00191	0.0403	CbGeAlD
Floxuridine—TYMS—vagina—ovarian cancer	0.00189	0.0401	CbGeAlD
Floxuridine—Zidovudine—TERT—ovarian cancer	0.00188	0.353	CrCbGaD
Floxuridine—TYMP—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.00172	0.0375	CbGpPWpGaD
Floxuridine—TYMS—testis—ovarian cancer	0.00169	0.0358	CbGeAlD
Floxuridine—TYMS—G1/S-Specific Transcription—CCNE1—ovarian cancer	0.00152	0.0332	CbGpPWpGaD
Floxuridine—TYMP—lymph node—ovarian cancer	0.00143	0.0302	CbGeAlD
Floxuridine—Trifluridine—TYMS—ovarian cancer	0.00127	0.24	CrCbGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00126	0.0275	CbGpPWpGaD
Floxuridine—TYMS—lymph node—ovarian cancer	0.00123	0.0259	CbGeAlD
Floxuridine—TYMP—Bladder Cancer—CDH1—ovarian cancer	0.00122	0.0267	CbGpPWpGaD
Floxuridine—TYMS—Paclitaxel—Docetaxel—ovarian cancer	0.00111	0.236	CbGdCrCtD
Floxuridine—TYMS—E2F transcription factor network—RBL2—ovarian cancer	0.00106	0.0232	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—ERBB2—ovarian cancer	0.00103	0.0225	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—CXCL8—ovarian cancer	0.000978	0.0213	CbGpPWpGaD
Floxuridine—TYMS—E2F mediated regulation of DNA replication—PPP2R1A—ovarian cancer	0.000966	0.0211	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—CCND1—ovarian cancer	0.000912	0.0199	CbGpPWpGaD
Floxuridine—TYMS—E2F mediated regulation of DNA replication—CCNE1—ovarian cancer	0.000897	0.0195	CbGpPWpGaD
Floxuridine—TYMP—Nucleotide metabolism—TYMS—ovarian cancer	0.000865	0.0189	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—VEGFA—ovarian cancer	0.000795	0.0173	CbGpPWpGaD
Floxuridine—TYMS—Vincristine—Vinorelbine—ovarian cancer	0.000763	0.162	CbGdCrCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000754	0.0164	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—MYC—ovarian cancer	0.000731	0.0159	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—MAPK1—ovarian cancer	0.000715	0.0156	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—EGFR—ovarian cancer	0.000715	0.0156	CbGpPWpGaD
Floxuridine—TYMS—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.000651	0.0142	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.000615	0.0134	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000614	0.0134	CbGpPWpGaD
Floxuridine—TYMS—Vinblastine—Vinorelbine—ovarian cancer	0.000613	0.13	CbGdCrCtD
Floxuridine—TYMP—Bladder Cancer—TP53—ovarian cancer	0.0006	0.0131	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—TOP1—ovarian cancer	0.00059	0.0129	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—HRAS—ovarian cancer	0.000574	0.0125	CbGpPWpGaD
Floxuridine—TYMP—Fluoropyrimidine Activity—TP53—ovarian cancer	0.000571	0.0124	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—BRCA1—ovarian cancer	0.000543	0.0118	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—PPP1CC—ovarian cancer	0.000515	0.0112	CbGpPWpGaD
Floxuridine—TYMS—G1/S Transition—SKP2—ovarian cancer	0.000514	0.0112	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—RSF1—ovarian cancer	0.000506	0.011	CbGpPWpGaD
Floxuridine—Embolism—Doxorubicin—ovarian cancer	0.000502	0.0037	CcSEcCtD
Floxuridine—Nail disorder—Doxorubicin—ovarian cancer	0.000497	0.00367	CcSEcCtD
Floxuridine—Stomatitis—Vinorelbine—ovarian cancer	0.000494	0.00364	CcSEcCtD
Floxuridine—Nystagmus—Epirubicin—ovarian cancer	0.000488	0.0036	CcSEcCtD
Floxuridine—Anaemia—Chlorambucil—ovarian cancer	0.00048	0.00355	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—CCNE1—ovarian cancer	0.000475	0.0104	CbGpPWpGaD
Floxuridine—Agranulocytosis—Vinorelbine—ovarian cancer	0.000473	0.00349	CcSEcCtD
Floxuridine—Alopecia—Topotecan—ovarian cancer	0.00047	0.00347	CcSEcCtD
Floxuridine—Leukopenia—Chlorambucil—ovarian cancer	0.000465	0.00343	CcSEcCtD
Floxuridine—Alopecia—Melphalan—ovarian cancer	0.00046	0.00339	CcSEcCtD
Floxuridine—Lethargy—Paclitaxel—ovarian cancer	0.000451	0.00333	CcSEcCtD
Floxuridine—Nystagmus—Doxorubicin—ovarian cancer	0.000451	0.00333	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—HNF1B—ovarian cancer	0.000447	0.00974	CbGpPWpGaD
Floxuridine—Muscle spasms—Topotecan—ovarian cancer	0.000445	0.00328	CcSEcCtD
Floxuridine—Abscess—Epirubicin—ovarian cancer	0.00044	0.00325	CcSEcCtD
Floxuridine—Thrombophlebitis—Docetaxel—ovarian cancer	0.000433	0.0032	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.000433	0.00944	CbGpPWpGaD
Floxuridine—Ill-defined disorder—Topotecan—ovarian cancer	0.000429	0.00317	CcSEcCtD
Floxuridine—Confusional state—Chlorambucil—ovarian cancer	0.000428	0.00316	CcSEcCtD
Floxuridine—Anaemia—Topotecan—ovarian cancer	0.000428	0.00316	CcSEcCtD
Floxuridine—Infection—Chlorambucil—ovarian cancer	0.000421	0.00311	CcSEcCtD
Floxuridine—Anaemia—Melphalan—ovarian cancer	0.000419	0.00309	CcSEcCtD
Floxuridine—Malaise—Topotecan—ovarian cancer	0.000417	0.00308	CcSEcCtD
Floxuridine—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000415	0.00307	CcSEcCtD
Floxuridine—Leukopenia—Topotecan—ovarian cancer	0.000414	0.00306	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.000413	0.009	CbGpPWpGaD
Floxuridine—Abscess—Doxorubicin—ovarian cancer	0.000407	0.00301	CcSEcCtD
Floxuridine—Leukopenia—Melphalan—ovarian cancer	0.000406	0.00299	CcSEcCtD
Floxuridine—Dry skin—Paclitaxel—ovarian cancer	0.000405	0.00299	CcSEcCtD
Floxuridine—Anorexia—Chlorambucil—ovarian cancer	0.000404	0.00298	CcSEcCtD
Floxuridine—Alopecia—Vinorelbine—ovarian cancer	0.000402	0.00297	CcSEcCtD
Floxuridine—Cramp muscle—Paclitaxel—ovarian cancer	0.000398	0.00294	CcSEcCtD
Floxuridine—Erythema—Vinorelbine—ovarian cancer	0.000396	0.00292	CcSEcCtD
Floxuridine—Discomfort—Topotecan—ovarian cancer	0.000389	0.00287	CcSEcCtD
Floxuridine—Lethargy—Docetaxel—ovarian cancer	0.000382	0.00282	CcSEcCtD
Floxuridine—Lacrimation increased—Epirubicin—ovarian cancer	0.000378	0.00279	CcSEcCtD
Floxuridine—Glossitis—Epirubicin—ovarian cancer	0.000378	0.00279	CcSEcCtD
Floxuridine—Anaphylactic shock—Topotecan—ovarian cancer	0.000378	0.00279	CcSEcCtD
Floxuridine—Infection—Topotecan—ovarian cancer	0.000375	0.00277	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—PPP2R1A—ovarian cancer	0.000371	0.0081	CbGpPWpGaD
Floxuridine—Nervous system disorder—Topotecan—ovarian cancer	0.00037	0.00273	CcSEcCtD
Floxuridine—Anaphylactic shock—Melphalan—ovarian cancer	0.00037	0.00273	CcSEcCtD
Floxuridine—Thrombocytopenia—Topotecan—ovarian cancer	0.00037	0.00273	CcSEcCtD
Floxuridine—Decreased appetite—Chlorambucil—ovarian cancer	0.000369	0.00272	CcSEcCtD
Floxuridine—Infection—Melphalan—ovarian cancer	0.000367	0.00271	CcSEcCtD
Floxuridine—Ill-defined disorder—Vinorelbine—ovarian cancer	0.000367	0.00271	CcSEcCtD
Floxuridine—Anaemia—Vinorelbine—ovarian cancer	0.000366	0.0027	CcSEcCtD
Floxuridine—Pancytopenia—Paclitaxel—ovarian cancer	0.000363	0.00268	CcSEcCtD
Floxuridine—Thrombocytopenia—Melphalan—ovarian cancer	0.000362	0.00267	CcSEcCtD
Floxuridine—Anorexia—Topotecan—ovarian cancer	0.00036	0.00266	CcSEcCtD
Floxuridine—Malaise—Vinorelbine—ovarian cancer	0.000357	0.00263	CcSEcCtD
Floxuridine—Leukopenia—Vinorelbine—ovarian cancer	0.000354	0.00262	CcSEcCtD
Floxuridine—Anorexia—Melphalan—ovarian cancer	0.000353	0.0026	CcSEcCtD
Floxuridine—Lacrimation increased—Doxorubicin—ovarian cancer	0.00035	0.00258	CcSEcCtD
Floxuridine—Glossitis—Doxorubicin—ovarian cancer	0.00035	0.00258	CcSEcCtD
Floxuridine—Feeling abnormal—Chlorambucil—ovarian cancer	0.00035	0.00258	CcSEcCtD
Floxuridine—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.000349	0.00257	CcSEcCtD
Floxuridine—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000347	0.00256	CcSEcCtD
Floxuridine—TYMP—Metabolism—NME2—ovarian cancer	0.000347	0.00755	CbGpPWpGaD
Floxuridine—TYMS—G1/S Transition—CCNE1—ovarian cancer	0.000345	0.00752	CbGpPWpGaD
Floxuridine—Dry skin—Docetaxel—ovarian cancer	0.000344	0.00254	CcSEcCtD
Floxuridine—Cramp muscle—Docetaxel—ovarian cancer	0.000337	0.00249	CcSEcCtD
Floxuridine—Body temperature increased—Chlorambucil—ovarian cancer	0.000335	0.00248	CcSEcCtD
Floxuridine—Abdominal pain—Chlorambucil—ovarian cancer	0.000335	0.00248	CcSEcCtD
Floxuridine—Discomfort—Vinorelbine—ovarian cancer	0.000333	0.00246	CcSEcCtD
Floxuridine—Stomatitis—Paclitaxel—ovarian cancer	0.000332	0.00245	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.000332	0.00723	CbGpPWpGaD
Floxuridine—Decreased appetite—Topotecan—ovarian cancer	0.000328	0.00242	CcSEcCtD
Floxuridine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000323	0.00238	CcSEcCtD
Floxuridine—Decreased appetite—Melphalan—ovarian cancer	0.000321	0.00237	CcSEcCtD
Floxuridine—Epistaxis—Paclitaxel—ovarian cancer	0.000321	0.00237	CcSEcCtD
Floxuridine—Infection—Vinorelbine—ovarian cancer	0.000321	0.00237	CcSEcCtD
Floxuridine—Nervous system disorder—Vinorelbine—ovarian cancer	0.000317	0.00234	CcSEcCtD
Floxuridine—Rash maculo-papular—Epirubicin—ovarian cancer	0.000317	0.00234	CcSEcCtD
Floxuridine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000316	0.00233	CcSEcCtD
Floxuridine—Angina pectoris—Docetaxel—ovarian cancer	0.000316	0.00233	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.000313	0.00682	CbGpPWpGaD
Floxuridine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000313	0.00231	CcSEcCtD
Floxuridine—Feeling abnormal—Topotecan—ovarian cancer	0.000311	0.0023	CcSEcCtD
Floxuridine—Gastrointestinal pain—Topotecan—ovarian cancer	0.000309	0.00228	CcSEcCtD
Floxuridine—Anorexia—Vinorelbine—ovarian cancer	0.000308	0.00227	CcSEcCtD
Floxuridine—Pancytopenia—Docetaxel—ovarian cancer	0.000308	0.00227	CcSEcCtD
Floxuridine—Haemoglobin—Paclitaxel—ovarian cancer	0.000307	0.00227	CcSEcCtD
Floxuridine—Haemorrhage—Paclitaxel—ovarian cancer	0.000306	0.00226	CcSEcCtD
Floxuridine—Asthenia—Chlorambucil—ovarian cancer	0.000304	0.00225	CcSEcCtD
Floxuridine—Pharyngitis—Paclitaxel—ovarian cancer	0.000304	0.00224	CcSEcCtD
Floxuridine—Abdominal pain—Topotecan—ovarian cancer	0.000299	0.0022	CcSEcCtD
Floxuridine—Body temperature increased—Topotecan—ovarian cancer	0.000299	0.0022	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000294	0.0064	CbGpPWpGaD
Floxuridine—Rash maculo-papular—Doxorubicin—ovarian cancer	0.000293	0.00216	CcSEcCtD
Floxuridine—TYMS—Fluoropyrimidine Activity—TP53—ovarian cancer	0.000292	0.00637	CbGpPWpGaD
Floxuridine—Thrombophlebitis—Epirubicin—ovarian cancer	0.000292	0.00216	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.000291	0.00633	CbGpPWpGaD
Floxuridine—Diarrhoea—Chlorambucil—ovarian cancer	0.00029	0.00214	CcSEcCtD
Floxuridine—Photosensitivity—Epirubicin—ovarian cancer	0.000288	0.00212	CcSEcCtD
Floxuridine—Stomatitis—Docetaxel—ovarian cancer	0.000282	0.00208	CcSEcCtD
Floxuridine—Decreased appetite—Vinorelbine—ovarian cancer	0.000281	0.00207	CcSEcCtD
Floxuridine—Hypersensitivity—Topotecan—ovarian cancer	0.000278	0.00205	CcSEcCtD
Floxuridine—Hypersensitivity—Melphalan—ovarian cancer	0.000272	0.00201	CcSEcCtD
Floxuridine—Epistaxis—Docetaxel—ovarian cancer	0.000272	0.00201	CcSEcCtD
Floxuridine—Asthenia—Topotecan—ovarian cancer	0.000271	0.002	CcSEcCtD
Floxuridine—Alopecia—Paclitaxel—ovarian cancer	0.00027	0.00199	CcSEcCtD
Floxuridine—Thrombophlebitis—Doxorubicin—ovarian cancer	0.00027	0.00199	CcSEcCtD
Floxuridine—Vomiting—Chlorambucil—ovarian cancer	0.00027	0.00199	CcSEcCtD
Floxuridine—Agranulocytosis—Docetaxel—ovarian cancer	0.00027	0.00199	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000268	0.00585	CbGpPWpGaD
Floxuridine—Photosensitivity—Doxorubicin—ovarian cancer	0.000266	0.00197	CcSEcCtD
Floxuridine—Erythema—Paclitaxel—ovarian cancer	0.000266	0.00197	CcSEcCtD
Floxuridine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000266	0.00197	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—RAD51C—ovarian cancer	0.000266	0.00579	CbGpPWpGaD
Floxuridine—Asthenia—Melphalan—ovarian cancer	0.000265	0.00196	CcSEcCtD
Floxuridine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000264	0.00195	CcSEcCtD
Floxuridine—Haemoglobin—Docetaxel—ovarian cancer	0.000261	0.00192	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.00026	0.00566	CbGpPWpGaD
Floxuridine—Haemorrhage—Docetaxel—ovarian cancer	0.000259	0.00191	CcSEcCtD
Floxuridine—Diarrhoea—Topotecan—ovarian cancer	0.000258	0.00191	CcSEcCtD
Floxuridine—Lethargy—Epirubicin—ovarian cancer	0.000258	0.0019	CcSEcCtD
Floxuridine—Pharyngitis—Docetaxel—ovarian cancer	0.000257	0.0019	CcSEcCtD
Floxuridine—Muscle spasms—Paclitaxel—ovarian cancer	0.000256	0.00189	CcSEcCtD
Floxuridine—Abdominal pain—Vinorelbine—ovarian cancer	0.000255	0.00189	CcSEcCtD
Floxuridine—Body temperature increased—Vinorelbine—ovarian cancer	0.000255	0.00189	CcSEcCtD
Floxuridine—Diarrhoea—Melphalan—ovarian cancer	0.000253	0.00187	CcSEcCtD
Floxuridine—Nausea—Chlorambucil—ovarian cancer	0.000252	0.00186	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000251	0.00548	CbGpPWpGaD
Floxuridine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000247	0.00182	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—CDKN1B—ovarian cancer	0.000246	0.00537	CbGpPWpGaD
Floxuridine—Anaemia—Paclitaxel—ovarian cancer	0.000246	0.00182	CcSEcCtD
Floxuridine—Vomiting—Topotecan—ovarian cancer	0.00024	0.00177	CcSEcCtD
Floxuridine—Malaise—Paclitaxel—ovarian cancer	0.00024	0.00177	CcSEcCtD
Floxuridine—Lethargy—Doxorubicin—ovarian cancer	0.000239	0.00176	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000239	0.0052	CbGpPWpGaD
Floxuridine—Leukopenia—Paclitaxel—ovarian cancer	0.000238	0.00176	CcSEcCtD
Floxuridine—Rash—Topotecan—ovarian cancer	0.000238	0.00176	CcSEcCtD
Floxuridine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000238	0.00176	CcSEcCtD
Floxuridine—Dermatitis—Topotecan—ovarian cancer	0.000238	0.00176	CcSEcCtD
Floxuridine—Headache—Topotecan—ovarian cancer	0.000237	0.00175	CcSEcCtD
Floxuridine—Vomiting—Melphalan—ovarian cancer	0.000235	0.00174	CcSEcCtD
Floxuridine—Rash—Melphalan—ovarian cancer	0.000233	0.00172	CcSEcCtD
Floxuridine—Dermatitis—Melphalan—ovarian cancer	0.000233	0.00172	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—PPP1CC—ovarian cancer	0.000232	0.00507	CbGpPWpGaD
Floxuridine—Asthenia—Vinorelbine—ovarian cancer	0.000232	0.00171	CcSEcCtD
Floxuridine—Dry skin—Epirubicin—ovarian cancer	0.000232	0.00171	CcSEcCtD
Floxuridine—Alopecia—Docetaxel—ovarian cancer	0.000229	0.00169	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000227	0.00495	CbGpPWpGaD
Floxuridine—Erythema—Docetaxel—ovarian cancer	0.000226	0.00167	CcSEcCtD
Floxuridine—Nausea—Topotecan—ovarian cancer	0.000224	0.00166	CcSEcCtD
Floxuridine—Discomfort—Paclitaxel—ovarian cancer	0.000224	0.00165	CcSEcCtD
Floxuridine—Gastritis—Epirubicin—ovarian cancer	0.000224	0.00165	CcSEcCtD
Floxuridine—TYMP—Metabolism—CYTB—ovarian cancer	0.000223	0.00487	CbGpPWpGaD
Floxuridine—Diarrhoea—Vinorelbine—ovarian cancer	0.000221	0.00163	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.00022	0.0048	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.00022	0.0048	CbGpPWpGaD
Floxuridine—Nausea—Melphalan—ovarian cancer	0.00022	0.00162	CcSEcCtD
Floxuridine—Confusional state—Paclitaxel—ovarian cancer	0.000219	0.00162	CcSEcCtD
Floxuridine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000217	0.0016	CcSEcCtD
Floxuridine—Muscle spasms—Docetaxel—ovarian cancer	0.000217	0.0016	CcSEcCtD
Floxuridine—Infection—Paclitaxel—ovarian cancer	0.000216	0.00159	CcSEcCtD
Floxuridine—Dry skin—Doxorubicin—ovarian cancer	0.000214	0.00158	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000214	0.00467	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—RBL2—ovarian cancer	0.000213	0.00465	CbGpPWpGaD
Floxuridine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000213	0.00157	CcSEcCtD
Floxuridine—Angina pectoris—Epirubicin—ovarian cancer	0.000213	0.00157	CcSEcCtD
Floxuridine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000213	0.00157	CcSEcCtD
Floxuridine—Anaemia—Docetaxel—ovarian cancer	0.000209	0.00154	CcSEcCtD
Floxuridine—Pancytopenia—Epirubicin—ovarian cancer	0.000207	0.00153	CcSEcCtD
Floxuridine—Anorexia—Paclitaxel—ovarian cancer	0.000207	0.00153	CcSEcCtD
Floxuridine—Gastritis—Doxorubicin—ovarian cancer	0.000207	0.00153	CcSEcCtD
Floxuridine—Vomiting—Vinorelbine—ovarian cancer	0.000205	0.00152	CcSEcCtD
Floxuridine—Zidovudine—ABCB1—ovarian cancer	0.000205	0.0385	CrCbGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000204	0.00445	CbGpPWpGaD
Floxuridine—Rash—Vinorelbine—ovarian cancer	0.000204	0.0015	CcSEcCtD
Floxuridine—Dermatitis—Vinorelbine—ovarian cancer	0.000204	0.0015	CcSEcCtD
Floxuridine—Headache—Vinorelbine—ovarian cancer	0.000202	0.00149	CcSEcCtD
Floxuridine—Leukopenia—Docetaxel—ovarian cancer	0.000202	0.00149	CcSEcCtD
Floxuridine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000199	0.00147	CcSEcCtD
Floxuridine—Angina pectoris—Doxorubicin—ovarian cancer	0.000197	0.00145	CcSEcCtD
Floxuridine—TYMP—Metabolism—PPP1CC—ovarian cancer	0.000195	0.00425	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—BRIP1—ovarian cancer	0.000195	0.00425	CbGpPWpGaD
Floxuridine—Pancytopenia—Doxorubicin—ovarian cancer	0.000192	0.00142	CcSEcCtD
Floxuridine—Nausea—Vinorelbine—ovarian cancer	0.000192	0.00142	CcSEcCtD
Floxuridine—Stomatitis—Epirubicin—ovarian cancer	0.00019	0.0014	CcSEcCtD
Floxuridine—Decreased appetite—Paclitaxel—ovarian cancer	0.000189	0.00139	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—MYC—ovarian cancer	0.000189	0.00411	CbGpPWpGaD
Floxuridine—Confusional state—Docetaxel—ovarian cancer	0.000186	0.00137	CcSEcCtD
Floxuridine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000185	0.00136	CcSEcCtD
Floxuridine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000184	0.00136	CcSEcCtD
Floxuridine—Epistaxis—Epirubicin—ovarian cancer	0.000184	0.00136	CcSEcCtD
Floxuridine—Infection—Docetaxel—ovarian cancer	0.000183	0.00135	CcSEcCtD
Floxuridine—Agranulocytosis—Epirubicin—ovarian cancer	0.000182	0.00134	CcSEcCtD
Floxuridine—Nervous system disorder—Docetaxel—ovarian cancer	0.000181	0.00133	CcSEcCtD
Floxuridine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00018	0.00133	CcSEcCtD
Floxuridine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000179	0.00132	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—CDKN1B—ovarian cancer	0.000179	0.0039	CbGpPWpGaD
Floxuridine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000178	0.00131	CcSEcCtD
Floxuridine—TYMS—Metabolism—NME2—ovarian cancer	0.000177	0.00386	CbGpPWpGaD
Floxuridine—Haemoglobin—Epirubicin—ovarian cancer	0.000176	0.0013	CcSEcCtD
Floxuridine—Stomatitis—Doxorubicin—ovarian cancer	0.000176	0.0013	CcSEcCtD
Floxuridine—Anorexia—Docetaxel—ovarian cancer	0.000176	0.0013	CcSEcCtD
Floxuridine—Haemorrhage—Epirubicin—ovarian cancer	0.000175	0.00129	CcSEcCtD
Floxuridine—Pharyngitis—Epirubicin—ovarian cancer	0.000174	0.00128	CcSEcCtD
Floxuridine—Body temperature increased—Paclitaxel—ovarian cancer	0.000172	0.00127	CcSEcCtD
Floxuridine—Abdominal pain—Paclitaxel—ovarian cancer	0.000172	0.00127	CcSEcCtD
Floxuridine—Epistaxis—Doxorubicin—ovarian cancer	0.00017	0.00125	CcSEcCtD
Floxuridine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000168	0.00124	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000168	0.00366	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000164	0.00357	CbGpPWpGaD
Floxuridine—Haemoglobin—Doxorubicin—ovarian cancer	0.000163	0.0012	CcSEcCtD
Floxuridine—Haemorrhage—Doxorubicin—ovarian cancer	0.000162	0.00119	CcSEcCtD
Floxuridine—Pharyngitis—Doxorubicin—ovarian cancer	0.000161	0.00119	CcSEcCtD
Floxuridine—Decreased appetite—Docetaxel—ovarian cancer	0.00016	0.00118	CcSEcCtD
Floxuridine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00016	0.00118	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000159	0.00346	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000159	0.00346	CbGpPWpGaD
Floxuridine—Asthenia—Paclitaxel—ovarian cancer	0.000156	0.00115	CcSEcCtD
Floxuridine—Alopecia—Epirubicin—ovarian cancer	0.000155	0.00114	CcSEcCtD
Floxuridine—Erythema—Epirubicin—ovarian cancer	0.000152	0.00112	CcSEcCtD
Floxuridine—Feeling abnormal—Docetaxel—ovarian cancer	0.000152	0.00112	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000151	0.00328	CbGpPWpGaD
Floxuridine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000151	0.00111	CcSEcCtD
Floxuridine—Diarrhoea—Paclitaxel—ovarian cancer	0.000149	0.0011	CcSEcCtD
Floxuridine—Muscle spasms—Epirubicin—ovarian cancer	0.000146	0.00108	CcSEcCtD
Floxuridine—Body temperature increased—Docetaxel—ovarian cancer	0.000146	0.00107	CcSEcCtD
Floxuridine—Abdominal pain—Docetaxel—ovarian cancer	0.000146	0.00107	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000144	0.00313	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—MLH1—ovarian cancer	0.000144	0.00313	CbGpPWpGaD
Floxuridine—Alopecia—Doxorubicin—ovarian cancer	0.000143	0.00106	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—SKP2—ovarian cancer	0.000142	0.00309	CbGpPWpGaD
Floxuridine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000141	0.00104	CcSEcCtD
Floxuridine—Erythema—Doxorubicin—ovarian cancer	0.000141	0.00104	CcSEcCtD
Floxuridine—Anaemia—Epirubicin—ovarian cancer	0.000141	0.00104	CcSEcCtD
Floxuridine—Vomiting—Paclitaxel—ovarian cancer	0.000138	0.00102	CcSEcCtD
Floxuridine—Malaise—Epirubicin—ovarian cancer	0.000137	0.00101	CcSEcCtD
Floxuridine—Rash—Paclitaxel—ovarian cancer	0.000137	0.00101	CcSEcCtD
Floxuridine—Dermatitis—Paclitaxel—ovarian cancer	0.000137	0.00101	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—MYC—ovarian cancer	0.000137	0.00298	CbGpPWpGaD
Floxuridine—Leukopenia—Epirubicin—ovarian cancer	0.000136	0.00101	CcSEcCtD
Floxuridine—Headache—Paclitaxel—ovarian cancer	0.000136	0.001	CcSEcCtD
Floxuridine—Hypersensitivity—Docetaxel—ovarian cancer	0.000136	0.001	CcSEcCtD
Floxuridine—Muscle spasms—Doxorubicin—ovarian cancer	0.000135	0.001	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000135	0.00293	CbGpPWpGaD
Floxuridine—Asthenia—Docetaxel—ovarian cancer	0.000132	0.000975	CcSEcCtD
Floxuridine—TYMP—Metabolism—YAP1—ovarian cancer	0.000131	0.00285	CbGpPWpGaD
Floxuridine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000131	0.000965	CcSEcCtD
Floxuridine—Anaemia—Doxorubicin—ovarian cancer	0.00013	0.000961	CcSEcCtD
Floxuridine—Nausea—Paclitaxel—ovarian cancer	0.000129	0.000953	CcSEcCtD
Floxuridine—Discomfort—Epirubicin—ovarian cancer	0.000128	0.000945	CcSEcCtD
Floxuridine—Malaise—Doxorubicin—ovarian cancer	0.000127	0.000938	CcSEcCtD
Floxuridine—Leukopenia—Doxorubicin—ovarian cancer	0.000126	0.000931	CcSEcCtD
Floxuridine—Diarrhoea—Docetaxel—ovarian cancer	0.000126	0.00093	CcSEcCtD
Floxuridine—Confusional state—Epirubicin—ovarian cancer	0.000125	0.000925	CcSEcCtD
Floxuridine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000124	0.000917	CcSEcCtD
Floxuridine—Infection—Epirubicin—ovarian cancer	0.000123	0.000911	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000123	0.00269	CbGpPWpGaD
Floxuridine—Nervous system disorder—Epirubicin—ovarian cancer	0.000122	0.000899	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000122	0.00265	CbGpPWpGaD
Floxuridine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000122	0.000898	CcSEcCtD
Floxuridine—Discomfort—Doxorubicin—ovarian cancer	0.000118	0.000874	CcSEcCtD
Floxuridine—Anorexia—Epirubicin—ovarian cancer	0.000118	0.000874	CcSEcCtD
Floxuridine—Vomiting—Docetaxel—ovarian cancer	0.000117	0.000864	CcSEcCtD
Floxuridine—Rash—Docetaxel—ovarian cancer	0.000116	0.000857	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—CHEK2—ovarian cancer	0.000116	0.00253	CbGpPWpGaD
Floxuridine—Dermatitis—Docetaxel—ovarian cancer	0.000116	0.000856	CcSEcCtD
Floxuridine—Confusional state—Doxorubicin—ovarian cancer	0.000116	0.000856	CcSEcCtD
Floxuridine—Headache—Docetaxel—ovarian cancer	0.000115	0.000852	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000115	0.00251	CbGpPWpGaD
Floxuridine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000115	0.000848	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000115	0.0025	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CYTB—ovarian cancer	0.000114	0.00249	CbGpPWpGaD
Floxuridine—Infection—Doxorubicin—ovarian cancer	0.000114	0.000843	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000114	0.00249	CbGpPWpGaD
Floxuridine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000113	0.000832	CcSEcCtD
Floxuridine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000113	0.000831	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000112	0.00244	CbGpPWpGaD
Floxuridine—Anorexia—Doxorubicin—ovarian cancer	0.00011	0.000809	CcSEcCtD
Floxuridine—Nausea—Docetaxel—ovarian cancer	0.000109	0.000808	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000109	0.00237	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—BRCA1—ovarian cancer	0.000109	0.00237	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CCND2—ovarian cancer	0.000109	0.00237	CbGpPWpGaD
Floxuridine—Decreased appetite—Epirubicin—ovarian cancer	0.000108	0.000797	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000108	0.00235	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—FASN—ovarian cancer	0.000107	0.00233	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000107	0.00232	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000105	0.00229	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—SLC5A5—ovarian cancer	0.000105	0.00229	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—PPP2R1A—ovarian cancer	0.000103	0.00224	CbGpPWpGaD
Floxuridine—Feeling abnormal—Epirubicin—ovarian cancer	0.000102	0.000756	CcSEcCtD
Floxuridine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000102	0.00075	CcSEcCtD
Floxuridine—TYMP—Metabolism—SLC2A1—ovarian cancer	0.000101	0.00221	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—PTEN—ovarian cancer	0.000101	0.0022	CbGpPWpGaD
Floxuridine—Decreased appetite—Doxorubicin—ovarian cancer	9.99e-05	0.000738	CcSEcCtD
Floxuridine—TYMS—Metabolism—PPP1CC—ovarian cancer	9.98e-05	0.00218	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—BRIP1—ovarian cancer	9.98e-05	0.00218	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—BRCA2—ovarian cancer	9.84e-05	0.00214	CbGpPWpGaD
Floxuridine—Body temperature increased—Epirubicin—ovarian cancer	9.82e-05	0.000725	CcSEcCtD
Floxuridine—Abdominal pain—Epirubicin—ovarian cancer	9.82e-05	0.000725	CcSEcCtD
Floxuridine—TYMP—Metabolism—CYP1B1—ovarian cancer	9.72e-05	0.00212	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CCNE1—ovarian cancer	9.53e-05	0.00208	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	9.49e-05	0.00207	CbGpPWpGaD
Floxuridine—Feeling abnormal—Doxorubicin—ovarian cancer	9.47e-05	0.000699	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—BIRC5—ovarian cancer	9.41e-05	0.00205	CbGpPWpGaD
Floxuridine—Gastrointestinal pain—Doxorubicin—ovarian cancer	9.4e-05	0.000694	CcSEcCtD
Floxuridine—Hypersensitivity—Epirubicin—ovarian cancer	9.15e-05	0.000676	CcSEcCtD
Floxuridine—Body temperature increased—Doxorubicin—ovarian cancer	9.09e-05	0.000671	CcSEcCtD
Floxuridine—Abdominal pain—Doxorubicin—ovarian cancer	9.09e-05	0.000671	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	8.98e-05	0.00196	CbGpPWpGaD
Floxuridine—Asthenia—Epirubicin—ovarian cancer	8.91e-05	0.000658	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.73e-05	0.0019	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PPP2R1A—ovarian cancer	8.62e-05	0.00188	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	8.54e-05	0.00186	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	8.54e-05	0.00186	CbGpPWpGaD
Floxuridine—Diarrhoea—Epirubicin—ovarian cancer	8.5e-05	0.000627	CcSEcCtD
Floxuridine—Hypersensitivity—Doxorubicin—ovarian cancer	8.47e-05	0.000625	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—BIRC5—ovarian cancer	8.42e-05	0.00183	CbGpPWpGaD
Floxuridine—Asthenia—Doxorubicin—ovarian cancer	8.25e-05	0.000609	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—TERT—ovarian cancer	8.15e-05	0.00178	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	8.07e-05	0.00176	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—ABCB1—ovarian cancer	8e-05	0.00174	CbGpPWpGaD
Floxuridine—Vomiting—Epirubicin—ovarian cancer	7.9e-05	0.000583	CcSEcCtD
Floxuridine—Diarrhoea—Doxorubicin—ovarian cancer	7.87e-05	0.000581	CcSEcCtD
Floxuridine—TYMP—Metabolism—TYMS—ovarian cancer	7.86e-05	0.00171	CbGpPWpGaD
Floxuridine—Rash—Epirubicin—ovarian cancer	7.83e-05	0.000578	CcSEcCtD
Floxuridine—Dermatitis—Epirubicin—ovarian cancer	7.83e-05	0.000578	CcSEcCtD
Floxuridine—Headache—Epirubicin—ovarian cancer	7.78e-05	0.000574	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	7.41e-05	0.00162	CbGpPWpGaD
Floxuridine—Nausea—Epirubicin—ovarian cancer	7.38e-05	0.000545	CcSEcCtD
Floxuridine—Vomiting—Doxorubicin—ovarian cancer	7.31e-05	0.000539	CcSEcCtD
Floxuridine—Rash—Doxorubicin—ovarian cancer	7.25e-05	0.000535	CcSEcCtD
Floxuridine—Dermatitis—Doxorubicin—ovarian cancer	7.24e-05	0.000534	CcSEcCtD
Floxuridine—Headache—Doxorubicin—ovarian cancer	7.2e-05	0.000532	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	7.17e-05	0.00156	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—TP53—ovarian cancer	6.89e-05	0.0015	CbGpPWpGaD
Floxuridine—Nausea—Doxorubicin—ovarian cancer	6.83e-05	0.000504	CcSEcCtD
Floxuridine—TYMS—Metabolism—YAP1—ovarian cancer	6.7e-05	0.00146	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CAV1—ovarian cancer	6.33e-05	0.00138	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—IL6—ovarian cancer	6.3e-05	0.00137	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	6.06e-05	0.00132	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PIK3CG—ovarian cancer	5.77e-05	0.00126	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	5.53e-05	0.0012	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—FASN—ovarian cancer	5.46e-05	0.00119	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—SLC5A5—ovarian cancer	5.37e-05	0.00117	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CCND1—ovarian cancer	5.27e-05	0.00115	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—SLC2A1—ovarian cancer	5.19e-05	0.00113	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PIK3CD—ovarian cancer	5.07e-05	0.00111	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CYP1B1—ovarian cancer	4.97e-05	0.00108	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CDKN1B—ovarian cancer	4.94e-05	0.00108	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CCND1—ovarian cancer	4.71e-05	0.00103	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PIK3CB—ovarian cancer	4.42e-05	0.000964	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PPP2R1A—ovarian cancer	4.41e-05	0.000961	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—MAPK3—ovarian cancer	4.35e-05	0.000947	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—MYC—ovarian cancer	4.23e-05	0.000921	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—MAPK1—ovarian cancer	4.14e-05	0.000901	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ABCB1—ovarian cancer	4.09e-05	0.000892	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—MAPK3—ovarian cancer	3.89e-05	0.000847	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PTEN—ovarian cancer	3.82e-05	0.000833	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—MYC—ovarian cancer	3.78e-05	0.000824	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—MAPK1—ovarian cancer	3.7e-05	0.000806	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CAV1—ovarian cancer	3.24e-05	0.000706	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—TP53—ovarian cancer	3.1e-05	0.000677	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PIK3CG—ovarian cancer	2.95e-05	0.000643	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PIK3CA—ovarian cancer	2.7e-05	0.000587	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PIK3CD—ovarian cancer	2.59e-05	0.000566	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PIK3CB—ovarian cancer	2.26e-05	0.000493	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—AKT1—ovarian cancer	2.2e-05	0.00048	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PTEN—ovarian cancer	1.95e-05	0.000426	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PIK3CA—ovarian cancer	1.38e-05	0.0003	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—AKT1—ovarian cancer	1.13e-05	0.000245	CbGpPWpGaD
